KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Short term Debt (2017 - 2026)

Amneal Pharmaceuticals has reported Short term Debt over the past 9 years, most recently at $7.2 million for Q3 2025.

  • For Q3 2025, Short term Debt fell 96.79% year-over-year to $7.2 million; the TTM value through Sep 2025 reached $7.2 million, down 96.79%, while the annual FY2024 figure was $100.0 million, 193.04% up from the prior year.
  • Short term Debt for Q3 2025 was $7.2 million at Amneal Pharmaceuticals, down from $31.2 million in the prior quarter.
  • Over five years, Short term Debt peaked at $290.0 million in Q1 2025 and troughed at $3.9 million in Q3 2022.
  • A 5-year average of $78.4 million and a median of $30.6 million in 2021 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: skyrocketed 689.58% in 2023 and later tumbled 96.79% in 2025.
  • Year by year, Short term Debt stood at $30.6 million in 2021, then fell by 2.13% to $30.0 million in 2022, then rose by 13.9% to $34.1 million in 2023, then soared by 193.04% to $100.0 million in 2024, then plummeted by 92.8% to $7.2 million in 2025.
  • Business Quant data shows Short term Debt for AMRX at $7.2 million in Q3 2025, $31.2 million in Q2 2025, and $290.0 million in Q1 2025.